High Risk-Human Papillomavirus in HNSCC: Present and Future Challenges for Epigenetic Therapies

Abstract

Head and Neck Squamous Cell Carcinoma (HNSCC) is a highly heterogeneous group of tumors characterized by an incidence of 650,000 new cases and 350,000 deaths per year worldwide and a male to female ratio of 3:1. The main risk factors are alcohol and tobacco consumption and Human Papillomavirus (HPV) infections. HNSCC cases are divided into two subgroups, the HPV-negative (HPV-) and the HPV-positive (HPV+) which have different clinicopathological and molecular profiles. However, patients are still treated with the same therapeutic regimens. It is thus of utmost importance to characterize the molecular mechanisms underlying these differences to find new biomarkers and novel therapeutic targets towards personalized therapies. Epigenetic alterations are a hallmark of cancer and can be exploited as both promising biomarkers and potential new targets. E6 and E7 HPV oncoviral proteins besides targeting p53 and pRb, impair the expression and the activity of several epigenetic regulators. While alterations in DNA methylation patterns have been well described in HPV+ and HPV- HNSCC, accurate histone post-translational modifications (hPTMs) characterization is still missing. Herein, we aim to provide an updated overview on the impact of HPV on the hPTMs landscape in HNSCC. Moreover, we will also discuss the sex and gender bias in HNSCC and how the epigenetic machinery could be involved in this process, and the importance of taking into account sex and/or gender also in this field.

Keywords: Head and Neck Squamous Cell Carcinoma (HNSCC); Human Papillomavirus (HPV); epigenetics; gender; head and neck cancer (HNC); histone post-translational modifications (hPTMs); sex; therapies.

Figure 1

Schematic representation of hr-HPV (HPV16/18) mediated cellular transformation of infected epithelial cells. E6: oncoviral protein E6; E7: oncoviral protein E7; E6AP: ubiquitin ligase E6 associated protein; p53: tumor suppressor protein p53; pRb: oncosuppressor protein pRb; E2F: E2F-1 transcription factor. Created with BioRender.com.